Trial · NCT07880756
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
NCT07880756, Phase 3, Recruiting, AbbVie
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness. Trials, record NCT07880756. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880756
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
- NCT number
- NCT07880756
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 150 participants, estimated
- Lead sponsor
- AbbVie
- Conditions
- Skin Quality
- Interventions
- NOA HYDRATION
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Responder Status Based on Evaluating Investigator (EI)'s Live Assessment of Allergan Cheek Smoothness Scale (ACSS) | Month 2 | Responder is defined as a participant with at least 1-point improvement (reduction) from Baseline on the ACSS on both cheeks. The ACSS is a validated 5-point scale developed to grade the severity of skin smoothness on the cheeks. The scale ranges from 0 (None: smooth skin) to 4 (Extreme: very rough skin with pronounced crevices). Higher scores indicate worse skin smoothness. |
| Primary | Percentage of Participants With Responder Status Based on Evaluating Investigator's Live Assessment Using the Global Aesthetic Improvement Scale (GAIS) | Month 2 | A responder is defined as a participant with improvement in the GAIS. The GAIS is used by the EI to assess global aesthetic improvement of the face. |
| Primary | Number of Participants With Adverse Events | Up to approximately 12 months | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
| Secondary | Percentage of Participants With Responder Status Based on Participant's Assessment Using the Global Aesthetic Improvement Scale (GAIS) | Month 2 | A responder is defined as a participant with improvement in the GAIS. The GAIS is used by the EI to assess global aesthetic improvement of the face. |
| Secondary | Change From Baseline in Overall Score of FACE-Q Satisfaction With Skin | Baseline to Month 2 | The FACE-Q Satisfaction with Skin is a validated questionnaire that assesses participant satisfaction with facial skin quality. Higher scores indicate greater satisfaction with skin. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880756
GET https://conductscience.org/api/trials/v1/NCT07880756/registered